SDMHF Stock Chart & Stats
$225.00
--
Market closed
$225.00
--
Day’s Range― - ―
52-Week Range$176.98 - $264.40
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$19.96B
Enterprise Value$19.29B
Total Cash (Recent Filing)$521.20M
Total Debt (Recent Filing)$2.61B
Price to Earnings (P/E)66.7
Beta0.78
Next Earnings
Jul 23, 2026EPS Estimate
1.44Next Dividend Ex-DateN/A
Dividend Yield0.29%
Share Statistics
EPS (TTM)2.75
Shares Outstanding97,330,410
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)5.00
Price to Sales (P/S)6.89
P/FCF Ratio140.53
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue6.46
Enterprise Value/Gross Profit14.45
Enterprise Value/Ebitda22.73
Forecast
1Y Price Target
$257.87Price Target Upside14.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)5.81
Revenue Forecast (FY)$3.63B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables BusinessSartorius Stedim's core consumables (single-use assemblies, filtration/purification disposables) create durable, repeatable revenue with strong customer stickiness and predictable pull-through after capital equipment placements, supporting long-term revenue visibility and margin stability.
Sharp TTM Revenue ReboundA 57% TTM revenue re-acceleration signals sustained recovery in end-market demand and expanding adoption of the firm's bioprocessing solutions; structurally this supports capacity utilization, installer momentum for equipment, and recurring consumable volumes over the medium term.
Healthy Operating ProfitabilityEBIT and EBITDA margins near 17% and 28% indicate operational efficiency and pricing power in core bioprocessing lines; such underlying profitability supports reinvestment, R&D and service capabilities and provides a buffer through industry cycles over months to quarters.
Bears Say
Margin And ROE Compression Vs PeaksMaterial deterioration from prior peak margins and sharply lower net margin and ROE reflect structural headwinds—pricing, mix shifts or cost base changes—that reduce capital returns and limit the company's ability to generate the high ROE seen in earlier years, weighing on long-term profitability.
Material Debt LoadAlthough leverage has improved, a sizeable €2.6B debt burden remains and constrains financial flexibility; ongoing interest and repayment needs can limit investments, M&A optionality or capital returns and increase sensitivity to slower cash generation over the medium term.
Weak Free-cash-flow ConversionRelatively low FCF conversion (35% of net income) indicates earnings do not fully translate to distributable cash, likely due to reinvestment or working-capital needs; this reduces ability to deleverage, fund growth or return capital, a structural constraint on financial resilience.
Sartorius Stedim Biotech News
SDMHF FAQ
What was Sartorius Stedim Biotech’s price range in the past 12 months?
Sartorius Stedim Biotech lowest stock price was $176.98 and its highest was $264.40 in the past 12 months.
What is Sartorius Stedim Biotech’s market cap?
Sartorius Stedim Biotech’s market cap is $19.96B.
When is Sartorius Stedim Biotech’s upcoming earnings report date?
Sartorius Stedim Biotech’s upcoming earnings report date is Jul 23, 2026 which is in 12 days.
How were Sartorius Stedim Biotech’s earnings last quarter?
Sartorius Stedim Biotech released its earnings results on Apr 23, 2026. The company reported $1.336 earnings per share for the quarter, missing the consensus estimate of $1.383 by -$0.047.
Is Sartorius Stedim Biotech overvalued?
According to Wall Street analysts Sartorius Stedim Biotech’s price is currently Undervalued.
Does Sartorius Stedim Biotech pay dividends?
Sartorius Stedim Biotech pays a Annually dividend of $0.801 which represents an annual dividend yield of 0.29%. See more information on Sartorius Stedim Biotech dividends here
What is Sartorius Stedim Biotech’s EPS estimate?
Sartorius Stedim Biotech’s EPS estimate is 1.44.
How many shares outstanding does Sartorius Stedim Biotech have?
Sartorius Stedim Biotech has 97,330,410 shares outstanding.
What happened to Sartorius Stedim Biotech’s price movement after its last earnings report?
Sartorius Stedim Biotech reported an EPS of $1.336 in its last earnings report, missing expectations of $1.383. Following the earnings report the stock price went down -13.855%.
Which hedge fund is a major shareholder of Sartorius Stedim Biotech?
Currently, no hedge funds are holding shares in SDMHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental components like cell lines, cell culture media, and bioreactors, alongside comprehensive solutions for separation, purification, and concentration processes. They also provide specialized systems for the safe storage and transport of biological intermediates and finished products. For advanced applications, particularly in cell and gene therapy, the company offers both single-use and reusable hollow-fiber membrane devices and presterilized assemblies. Beyond physical products, their service offerings cover vital bioprocessing steps such as cell cultivation, fermentation, filtration, purification, and fluid management, in addition to cell harvesting and broader solutions for intensified bioprocesses. Furthermore, Sartorius Stedim Biotech provides advanced data analytics software designed to model and optimize biopharmaceutical development and production workflows. Serving a diverse customer base, including pharmaceutical, food, and chemical manufacturers, as well as research and development laboratories, the company was founded in 1870 and operates from its headquarters in Aubagne, France.
SDMHF Stock 12 Month Forecast
Average Price Target
$257.87
▲(14.61% Upside)
Ownership Overview
― Insiders
3.01% Mutual Funds
<0.01% Other Institutional Investors
94.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---